ArticleScientific reports2025
Construction of a novel tool for predicting chronic obstructive pulmonary disease mortality in lung cancer patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rate of lung cancer patients with chronic obstructive pulmonary disease (COPD) is increasing. This study aimed to identify the risk factors associated with COPD mortality in lung cancer patients and to develop a practical tool to achieve an accurate prediction of COPD mortality in lung cancer patients. Patient-related data for this study were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Risk factors for COPD mortality were identified using Cox regression analysis. The Kaplan-Meier curves were depicted to further validate associated risk factors. Variables screened by multivariate Cox regression analysis were used to construct a predictive model for the risk of COPD mortality. The performance of the model was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and its clinical applicability was evaluated using decision curve analysis (DCA). 28,194 patients were randomized in a 7:3 ratio into a training cohort (n = 19,736) and a validation cohort (n = 8458). Cox regression analysis showed age, race, sex, grade, histological type, T stage, N stage, surgery, chemotherapy, bone metastasis, and marital status as independent factors influencing COPD mortality. The area under the curve (AUC) values of the model in the training cohort were 0.886, 0.870, and 0.873, respectively. In the validation cohort, the AUC values were 0.901, 0.888, and 0.879, respectively. The calibration curves further demonstrate the reliability and stability of the model. DCA indicated that the model could achieve more net clinical benefit. A clinical model for predicting the risk of COPD mortality in lung cancer patients was further constructed, which could provide risk assessment and clinical decision-making for individualized treatment of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.